In particular, the immunization with mD8-FAT1 combined with EGFRvIII, a B cell epitope expressed in a variety of tumors in which the EGF receptor undergoes the deletion of its ectodomain (22), almost fully abrogated tumor development in C57bl6 mice challenged with B16F10-EGFRvIII, a cell line expressing both mD8-FAT1 and EGFRvIII. Here, FAT1 is linked to neoplasm.